BEVERLY HILLS, Calif.,
March 12, 2015 /PRNewswire/
-- Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich
Pharmaceuticals" or the "Company"), a clinical-stage biotechnology
company focused on developing innovative therapies in oncology,
with initial concentration in treating Acute Myelocytic Leukemia
(AML) and Hodgkin's Lymphoma, announced that Dr. Chittima
Sirijerachai has committed to becoming a principal investigator
(PI) for the upcoming AML clinical trial utilizing Rich's flagship
compound RP-323.
As a principal investigator, Dr. Sirijerachai will enroll
patients and serve as a liaison for Rich Pharmaceuticals and
supervise some of Rich's clinical study initiatives outside
the United States. Dr.
Sirijerachai received her Diploma in Medical Education from the
University Of Wales College Of Medicine, Cardiff, England and Diplomas from the Thai Board of
Hematology and Internal Medicine at the Royal College of Physician
of Thailand and is currently on
the Faculty of Medicine at Khon-Kaen University.
"We are honored to have Dr. Chittima Sirijerachai agree to
become a PI for Rich Pharmaceuticals," said Ben Chang, Chief Executive Officer of the
Company. "We greatly value her expertise and guidance in our
planned clinical trials. In addition, we continue to
aggressively push ahead with our AML clinical plans and with
Therinova's clinical research expertise in oncology, we are
confident in our regulatory approval strategy," continued
Ben Chang.
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (OTCQB: RCHA) is a biopharmaceutical
company developing a treatment for
Acute Myelocytic Leukemia (AML)/white blood cell
elevation, Hodgkin's Lymphoma and other blood related
diseases. Rich Pharmaceuticals' goal is to extend refractory
patients life expectancy and increase quality of life. Rich
Pharmaceuticals' primary development stage product candidate,
RP-323, is being designed to treat
blood and cancer related diseases through non-evasive outpatient
facilities. Find out more at www.richpharmaceuticals.com.
For more information about AML see for example:
http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/Patient/page1
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/
For more information about Hodgkin's Lymphoma see for
example:
http://www.cancer.gov/cancertopics/types/hodgkin
http://www.cancer.org/cancer/hodgkindisease/
Notice Regarding Forward-Looking Statements:
This news release contains "forward-looking statements" as that
term is defined in Section 27(a) of the Securities Act of 1933, as
amended, and Section 21(e) of the Securities Exchange Act of 1934,
as amended. Statements in this press release that are not purely
historical are forward-looking statements and include any
statements regarding beliefs, plans, expectations or intentions
regarding the future. Such forward-looking statements include,
among other things, references to novel technologies and methods,
our business and product development plans, our financial
projections or market information. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or
technologies and operating as a development stage company, our
ability to raise the additional funding we will need to continue to
pursue our business and product development plans, our ability to
develop and commercialize products based on our technology
platform, competition in the industry in which we operate and
market conditions. These forward-looking statements are made as of
the date of this news release, and we assume no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein
and should also refer to the risk factors disclosure outlined in
the reports and other documents we file with the SEC, available at
www.sec.gov.
Contact: Ben Chang, CEO,
424-230-7001 EXT 105
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rich-pharmaceuticals-inc-names-chittima-sirijerachai-md-as-principal-investigator-for-upcoming-aml-clinical-trials-300049629.html
SOURCE Rich Pharmaceuticals, Inc.